EFPIA STANDARD REPORT  Date of publication: 27/05/2025												
	Full Name	HCPs: City of Principal Practice HCOs: city where registered		Principal Practice Address	Unique country identifier OPTIONAL	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy		TOTAL OPTIONAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration fees	Travel & Accomodation	Fees	agreed in the fee for service or consultancy contract, including travel &	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											le for the
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
HCPs	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A	46 664 лв	124 544 лв	98 728 лв	21 696 лв	291 633 лв
	Number of Recipients in aggregate disclosure - Art. 3.02					N/A	N/A	56	72	63	24	126
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A	100%	100%	100%	100%	N/A
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
HCOs	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02				12 500 лв	413 484 лв			301 380 лв		727 365 лв	
I	Number of Recipients in aggregate disclosure - Art. 3.02				1	13			3		16	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					100%	100%			100%		N/A
R&D		AGGREGATE DISCLOSURE										
R		Transfers of Value Research & Development as defined - Article 3.04 and Schedule 1										1 018 998 лв